One of The Best Dividend Stocks from the USA You’ve Never Heard Of
🔥 Hidden Innovator in Vascular Surgery with 14 Years of Double-Digit Dividend Growth 🔥
When a stock checks every box – and still flies under the radar – you know you’ve found something special. Our latest Focus Stock from the USA, also one of the Dividend Heroes, is an absolute hidden gem with jaw-dropping numbers:
✅ 14 YEARS of uninterrupted double digit dividend increases
✅ A massive 25% dividend hike announced for 2025 – this year! (no other dividend hero comes close….)
✅ 400% dividend growth over the past decade
✅ An insane 1000% stock price surge over the same period
✅ A blazing 16.4% 10-year CAGR for the dividend
But here's the kicker: despite these stellar stats, the stock is down 8% YTD. This is a golden buy the dip opportunity, and it's flying under the radar of the big investors—for now. With a market cap of just $1.9 billion, it won’t stay hidden for long.
Throw in a solid EBIT margin over 25%, a rock-solid track record, and 11 analysts following it with NOT A SINGLE SELL RATING, and it’s clear: this Dividend Hero is just getting started.
This is the kind of stock you want to own for the long haul. Let’s dive into why it’s set to soar to even greater heights in the coming years.
The stock we are talking about is LeMaitre Vascular (LMAT), one of the Dividend Heroes in 2025. We like the stock because of its strong margins, revenue growth, solid balance sheet and most important: impressive dividend growth with LMAT now having raised the dividend for 14 consecutive years with a double digit hike every single year. Even better: they just announced a 25% hike for 2025, the biggest increase since 2018.
Inside LeMaitre Vascular: A Global Player in Peripheral Vascular Solutions
LeMaitre Vascular, Inc. LMAT 0.00%↑ is a medical device company focused on serving vascular surgeons and related specialists through a broad portfolio of devices, implants, and services. Headquartered in Massachusetts and operating in over 90 countries, the company provides tools to diagnose, treat, and support patients with peripheral vascular disease—a condition affecting arteries and veins outside the heart and brain.
Business Overview
LeMaitre develops, manufactures, and markets products specifically designed for open vascular surgery and dialysis access. Its offerings are used not only by vascular surgeons, but also by cardiac surgeons, general surgeons, and neurosurgeons. The company’s diverse product lineup includes:
Anastomotic clips
Biologic vascular and dialysis grafts
Biologic vascular and cardiac patches
Carotid shunts
Embolectomy and occlusion catheters
Radiopaque marking tape
Synthetic vascular and dialysis grafts
Valvulotomes (now in its seventh generation)
Beyond hardware, LeMaitre also provides cryopreservation services for human vascular and cardiac tissue, contributing to its integrated service model in vascular care.
LeMaitre competes in a niche but crowded field. Competitors include larger multinational medtech firms like Medtronic MDT 0.00%↑ , BD (Becton Dickinson) BDX 0.00%↑ , and Getinge (from Sweden), as well as smaller specialized vascular companies. However, LeMaitre differentiates itself through its targeted product portfolio, direct relationships with vascular surgeons, and a disciplined acquisition strategy.
Historical Context and Evolution
The company was founded around the invention of a new type of valvulotome by Dr. George LeMaitre, aimed at improving outcomes in vascular surgery. Over time, this innovation became the cornerstone of a broader strategy combining organic growth with acquisitive expansion. George LeMaitre still holds 1.89 million shares of the company, worth $159 million at current stock prices (a 8.4% stake).
Since inception, LeMaitre has completed 24 acquisitions over the past 27 years, allowing it to expand both its product offerings and its global reach. Its business model emphasizes agility, often attributed to a deliberate effort to retain a small-company culture. Decision-making is decentralized, and internal collaboration is emphasized across functions.
Market Position and Footprint
LeMaitre holds #1 or #2 market share in 9 out of 12 niche segments it competes in. The company’s products are sold primarily in the United States, Europe, Canada, and the Asia Pacific region, supported by a large and growing sales force that reaches specialists in 29 countries.
A key focus area for the company is the strategic shift toward biologics and products commonly used by cardiac surgeons, supplementing its strong base in vascular surgical devices. LeMaitre’s mix of single-use devices and implants also provides revenue resilience and diversification.
Growth Dynamics
LeMaitre’s growth strategy is powered by several drivers:
Sales force expansion
Price increases
Regulatory approvals
Acquisitions and distributor buyouts
This approach has helped support consistent sales growth and a track record of profitability.
The company maintains an attractive operating margin, strong cash generation, and participates in the NASDAQ US Broad Dividend Achievers Index, signaling a history of dividend growth.
As of the most recent data, LeMaitre holds approximately $300 million in cash, positioning it for continued investment in innovation and acquisition.
Fundamentals and Dividend
LMAT is a relatively small company, with a market capitalization of $1.9 billion as of April 21, 2025, based on a share price of $84.72. Although its estimated P/E ratio of 38 for 2025 suggests a relatively high valuation, LMAT is growing rapidly. Analysts forecast annual revenue growth of 8-9% over the next four years. With a strong balance sheet and healthy profit margins, the company’s growing free cash flow offers more than enough room for further dividend increases.
When it comes to dividend growth, LMAT stands out: the company has raised its dividend 14 years in a row, with a 25% increase announced this year. This type of growth is rare and positions LMAT as a standout player. As a result, the stock price has risen significantly, reflecting the company’s strong fundamentals, much like Dividend Aristocrat Cintas CTAS 0.00%↑ .
LMAT is expected to pay out around $18 million in dividends annually, while its free cash flow is projected to exceed $56 million in 2025, leaving substantial room for additional dividend hikes and acquisitions. The only real drawback is that LMAT does not do buybacks, but this doesn’t overshadow its overall growth prospects.
The recent stock price pullback is in line with the broader trend of top-performing stocks facing corrections. We like the stock and LMAT is (again) one of the Dividend Heroes in 2025. That says just about enough…….
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Investors should conduct their own research or consult with a financial advisor before making any investment decisions.